


The number of individual cases identified in EudraVigilance for COVID-19 VACCINE JANSSEN (AD26.COV2.S) is 70,228 (up to 03/12/2022)


Number of individual cases by Age Group

Age Group	Cases	%
Not Specified	4,909	7.0%
0-1 Month	17	0.0%
2 Months - 2 Years	56	0.1%
3-11 Years	6	0.0%
12-17 Years	118	0.2%
18-64 Years	60,260	85.8%
65-85 Years	4,456	6.3%
More than 85 Years	406	0.6%
Total	70,228	100.0%




Number of individual cases by Sex

Sex	Cases	%
Female	37,206	53.0%
Male	30,258	43.1%
Not Specified	2,764	3.9%
Total	70,228	100.0%




Number of individual cases by Geographic Origin (EEA/Non-EEA)

Occurrence Country EEA/Non EEA	Cases	%
European Economic Area	58,333	83.1%
Non European Economic Area	11,895	16.9%
Not Specified	0	
Total	70,228	100.0%




Reporter Group	Cases	%
Healthcare Professional	27,008	38.5%
Non Healthcare Professional	43,220	61.5%
Not Specified	0	
Total	70,228	100.0%

Number of individual cases by Reporter Group



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu



Number of individual cases identified in EudraVigilance received over the last 12 months and overall for
COVID-19 VACCINE JANSSEN (AD26.COV2.S) (up to 03/12/2022)



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu


Number of individual cases identified in EudraVigilance in EEA countries for COVID-19 VACCINE JANSSEN (AD26.COV2.S) (up to 03/12/2022)

The country is not displayed if the number of cases is less or equal to 3 for that country



For the interpretation of the results, please refer to the key considerations at www.adreports.eu

Choose how you want to see the number of individual cases identified in EudraVigilance for COVID-19 VACCINE JANSSEN (AD26.COV2.S) (up to 03/12/2022)



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu